Podcast: ‘What The Health?’ Why Is It So Difficult To Control Drug Prices?

Clockwise from left, Mary Agnes Carey of Kaiser Health News, Margot Sanger-Katz of The New York Times, Julie Appleby of KHN, and Sarah Karlin-Smith of Politico. (Caitlin Hillyard/KHN)

Mary Agnes Carey of Kaiser Health News, Sarah Karlin-Smith of Politico, Margot Sanger-Katz of The New York Times and Julie Appleby of Kaiser Health News discuss the recent extension of cost-sharing subsidies for millions of low-income beneficiaries on the Affordable Care Act’s marketplaces — as well as the state of play on Capitol Hill and in the states concerning efforts to lower prescription drug costs.

Plus, for “extra credit,� the panelists recommend their favorite health stories of the week they think you should read, too.

Mary Agnes Carey:ÌýKaiser Health News’ “,” by JoNel Aleccia.

Margot Sanger-Katz:Ìýµþ±ô´Ç´Ç³¾²ú±ð°ù²µ’²õÌý“,” by Hannah Recht.

Sarah Karlin-Smith: TheÌýNew York Times’Ìý“,”Ìýby Gina Kolata.

Julie Appleby: TheÌýWall Street Journal’sÌý“,”Ìýby Denise Roland.

To hear all our podcasts,Ìý.

And subscribe to What the Health? onÌý,ÌýÌýorÌý.

Related Topics

Health IndustryAffordable Care ActDrug CostsDrugsMultimediaÑî¹óåú´«Ã½Ò•îlSubsidiesU.S. CongressRepeal And Replace WatchWhat the Health? From Ñî¹óåú´«Ã½Ò•îl Health News

More from Ñî¹óåú´«Ã½Ò•îl Health News

Ñî¹óåú´«Ã½Ò•îl Health News & PolitiFact HealthCheck

Trump Exaggerates Speed and Certainty of Prescription Drug Price Reductions

According to the timeline in the May 12 executive order, prescription drug price reductions would not happen "almost immediately,� but rather could take months or years. And extending the savings to Americans outside federal health insurance programs such as Medicare would likely require congressional action.